Perceptive Advisors LLC trimmed its stake in shares of TESARO Inc (NASDAQ:TSRO) by 66.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 129,372 shares of the biopharmaceutical company’s stock after selling 259,279 shares during the quarter. Perceptive Advisors LLC owned about 0.24% of TESARO worth $10,721,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently made changes to their positions in the company. KBC Group NV raised its position in shares of TESARO by 10.9% during the 3rd quarter. KBC Group NV now owns 5,606 shares of the biopharmaceutical company’s stock worth $724,000 after purchasing an additional 553 shares during the period. State Board of Administration of Florida Retirement System raised its position in shares of TESARO by 1.2% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 49,054 shares of the biopharmaceutical company’s stock worth $6,333,000 after purchasing an additional 570 shares during the period. Pacer Advisors Inc. raised its position in shares of TESARO by 24.1% during the 3rd quarter. Pacer Advisors Inc. now owns 5,372 shares of the biopharmaceutical company’s stock worth $694,000 after purchasing an additional 1,043 shares during the period. Legal & General Group Plc increased its position in TESARO by 2.9% in the 3rd quarter. Legal & General Group Plc now owns 38,297 shares of the biopharmaceutical company’s stock valued at $4,944,000 after acquiring an additional 1,079 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in TESARO by 13.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,200 shares of the biopharmaceutical company’s stock valued at $1,188,000 after acquiring an additional 1,100 shares during the period.
TSRO has been the topic of several analyst reports. Leerink Swann upgraded TESARO from a “market perform” rating to an “outperform” rating in a research report on Wednesday, November 15th. HC Wainwright restated a “buy” rating and issued a $158.00 target price on shares of TESARO in a research report on Monday, November 20th. Argus set a $154.00 target price on TESARO and gave the company a “buy” rating in a research report on Tuesday, November 28th. Citigroup restated a “buy” rating and issued a $135.00 target price (down from $216.00) on shares of TESARO in a research report on Wednesday, December 20th. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $80.00 target price on shares of TESARO in a research report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $133.39.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.96). The firm had revenue of $48.02 million for the quarter, compared to the consensus estimate of $51.78 million. TESARO had a negative net margin of 222.15% and a negative return on equity of 126.44%. research analysts predict that TESARO Inc will post -9.54 earnings per share for the current fiscal year.
In other TESARO news, VP Grant C. Bogle sold 1,809 shares of the stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $54.85, for a total transaction of $99,223.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Orlando Oliveira sold 3,000 shares of the firm’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $69.88, for a total value of $209,640.00. Following the sale, the senior vice president now directly owns 9,076 shares of the company’s stock, valued at $634,230.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 334,913 shares of company stock valued at $19,083,294 and have sold 13,042 shares valued at $760,526. Company insiders own 34.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Perceptive Advisors LLC Reduces Stake in TESARO Inc (TSRO)” was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/03/12/perceptive-advisors-llc-reduces-stake-in-tesaro-inc-tsro.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.